公开(公告)号：WO2009052323A3

公开(公告)日：2009-09-11

申请号：PCT/US2008080221

申请日：2008-10-16

Applicant: PHARMACYCLICS INC ,  LOURY DAVID ,  PURRO NORBERT

Inventor： LOURY DAVID ,  PURRO NORBERT

IPC: C07K14/76 ,  A61K35/14 ,  A61K38/48 ,  C07K14/00

CPC classification number: A61K31/4184 ,  A61K31/4164 ,  A61K41/00 ,  A61K45/06 ,  C07D209/00 ,  C07D235/12 ,  C07D235/18 ,  A61K2300/00

Abstract: Treatment of cancer and thromboembolic disorders using inhibitors of Factor VIIa are disclosed herein using a compound of Formula I.

Abstract translation: 本文使用式I化合物公开了使用因子VIIa抑制剂治疗癌症和血栓栓塞障碍。

公开(公告)号：EP2209801A4

公开(公告)日：2011-04-06

申请号：EP08839610

申请日：2008-10-16

Applicant: PHARMACYCLICS INC

Inventor： LOURY DAVID ,  PURRO NORBERT

IPC: C07K14/76 ,  A61K35/14 ,  A61K38/48 ,  A61M5/178 ,  C07K14/00

CPC classification number: A61K31/4184 ,  A61K31/4164 ,  A61K41/00 ,  A61K45/06 ,  C07D209/00 ,  C07D235/12 ,  C07D235/18 ,  A61K2300/00

公开(公告)号：EP2755648A4

公开(公告)日：2015-03-11

申请号：EP11872389

申请日：2011-09-13

Applicant: PHARMACYCLICS INC ,  SERVIER SAS LAB

Inventor： LOURY DAVID J ,  BUGGY JOSEPH J ,  MODY TARAK D ,  VERNER ERIK J ,  PURRO NORBERT ,  BALASUBRAMANIAN SRIRAM ,  KLOOS IOANA ,  DEPIL STÉPHANE

IPC: A61K31/343 ,  A61K31/16 ,  A61K31/166 ,  A61P35/00

CPC classification number: A61K31/343 ,  A61K9/14 ,  A61K9/28 ,  A61K9/70 ,  A61K31/4184 ,  A61K2300/00

公开(公告)号：EP2854859A4

公开(公告)日：2016-01-13

申请号：EP13799982

申请日：2013-06-03

Applicant: PHARMACYCLICS INC

Inventor： PURRO NORBERT ,  SMYTH MARK ,  GOLDMAN ERICK ,  WIRTH DAVID D

IPC: A61K9/20 ,  A61K9/48 ,  A61K31/519 ,  A61K45/06 ,  A61P29/00 ,  A61P35/00 ,  C07D487/04

CPC classification number: C07D487/04 ,  A61J1/035 ,  A61K9/0053 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/4825 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/519 ,  A61K45/06 ,  B65D75/36 ,  C07B2200/13 ,  A61K2300/00

Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Abstract translation: 本文描述了Bruton的酪氨酸激酶（Btk）抑制剂1 - （（R）-3-（4-氨基-3-（4-苯氧基苯基）-1H-吡唑并[3,4-d]嘧啶-1-基）哌啶 -1-基）丙-2-烯-1-酮，包括结晶形式，溶剂化物和药学上可接受的盐。 还公开了包括Btk抑制剂的药物组合物，以及使用Btk抑制剂单独或与其它治疗剂组合用于治疗自身免疫性疾病或病症，异种免疫疾病或病症，癌症（包括淋巴瘤）和 炎性疾病或病症。

公开(公告)号：HK1208803A1

公开(公告)日：2016-03-18

申请号：HK15109505

申请日：2015-09-25

Applicant: PHARMACYCLICS INC

Inventor： SMYTH MARK ,  GOLDMAN ERICK ,  WIRTH DAVID D ,  PURRO NORBERT

IPC: A61K20060101 ,  A61P20060101

Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

公开(公告)号：CO7240408A2

公开(公告)日：2015-04-17

申请号：CO14276324

申请日：2014-12-16

Applicant: PHARMACYCLICS INC

Inventor： SMYTH MARK ,  GOLDMAN ERICK ,  WIRTH DAVID D ,  PURRO NORBERT

IPC: A61K47/38 ,  C07D487/04

Abstract: Se describe aquí al inhibidor de tirosina quinasa(Btk) de Bruton 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1Hpirazolo[3,4-d] pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona, incluyendo las formas cristalinas, solvatos y sussales aceptables en el campo farmacéutico. Se describetambién composiciones farmacéuticas que incluyen alinhibidor Btk, así como métodos para usar a dicho inhibidorsolo o en combinación con otros agentes terapéuticos, parael tratamiento de enfermedades o condiciones autoinmunes,enfermedades o condiciones heteroinmunes, cáncer,incluyendo linfoma, así como enfermedades o condicionesinflamatorias.

公开(公告)号：AU2013271918A8

公开(公告)日：2015-02-26

申请号：AU2013271918

申请日：2013-06-03

Applicant: PHARMACYCLICS INC

Inventor： SMYTH MARK ,  GOLDMAN ERICK ,  WIRTH DAVID D ,  PURRO NORBERT

IPC: A61K47/38 ,  A61K9/48 ,  A61K47/30 ,  A61P29/00 ,  A61P35/00

Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

公开(公告)号：CA2875986A1

公开(公告)日：2013-12-12

申请号：CA2875986

申请日：2013-06-03

Applicant: PHARMACYCLICS INC

Inventor： PURRO NORBERT ,  SMYTH MARK ,  GOLDMAN ERICK ,  WIRTH DAVID D

IPC: A61K47/38 ,  A61K9/48 ,  A61K47/30 ,  A61P29/00 ,  A61P35/00

Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

公开(公告)号：GB2430620A

公开(公告)日：2007-04-04

申请号：GB0521612

申请日：2005-10-24

Applicant: PHARMACYCLICS INC

Inventor： PURRO NORBERT ,  MADDEN HUGO ,  NGUYEN SUZANNE KRETCHMAR

IPC: A61J1/00 ,  A61J1/14 ,  A61K9/00 ,  B65D77/04 ,  B65D81/30

Abstract: A packaging system is described for a drug that provides protection from contamination, crystallization and/or degradation of the drug during storage of the system prior to its use. The packaging of the drug does not significantly absorb, react with, or otherwise adversely affect the therapeutic effectiveness of the drug or other excipients or components during storage of the system prior to its use. The packaging system is also used for preserving a drug, particularly a drug containing high-purity texaphyrin metal complexes, by providing a product packaging system that prevents, limits or otherwise controls degradation reactions that can result from exposure to oxygen and/or light.

公开(公告)号：CL2017000371A1

公开(公告)日：2017-10-30

申请号：CL2017000371

申请日：2017-02-13

Applicant: PHARMACYCLICS INC

Inventor： SMYTH MARK ,  GOLDMAN ERICK ,  WIRTH DAVID D ,  PURRO NORBERT

IPC: A61K47/30 ,  A61K9/48 ,  A61K47/38

Abstract: SE DESCRIBE AQUÍ AL INHIBIDOR DE TIROSINA QUINASA (BTK) DE BRUTON 1-((R)-3-(4-AMINO-3-(4-FENOXIFENIL)-1 H-PIRALOLO[3,4- D] PIRIMIDIN-1-IL)PIPERIDIN-1-IL)PROP-2-EN-1 -ONA, INCLUYENDO LAS FORMAS CRISTALINAS, SOLVATOS Y SUS SALES ACEPTABLES EN EL CAMPO FARMACÉUTICO. SE DESCRIBE TAMBIÉN COMPOSICIONES FARMACÉUTICAS QUE INCLUYEN AL INHIBIDOR BTK, ASÍ COMO MÉTODOS PARA USAR A DICHO INHIBIDOR SOLO O EN COMBINACIÓN CON OTROS AGENTES TERAPÉUTICOS, PARA EL TRATAMIENTO DE ENFERMEDADES O CONDICIONES AUTOINMUNES, ENFERMEDADES O CONDICIONES HETEROINMUNES, CÁNCER, INCLUYENDO LINFOMA, ASÍ COMO ENFERMEDADES O CONDICIONES INFLAMATORIAS.